Compare JILL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JILL | CRBU |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.1M | 203.9M |
| IPO Year | 2017 | 2021 |
| Metric | JILL | CRBU |
|---|---|---|
| Price | $16.92 | $1.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $18.50 | $8.50 |
| AVG Volume (30 Days) | 122.2K | ★ 1.1M |
| Earning Date | 12-10-2025 | 03-09-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $600,981,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | $0.22 |
| Revenue Next Year | $2.43 | $4.48 |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.32 | $0.66 |
| 52 Week High | $28.94 | $3.54 |
| Indicator | JILL | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 70.78 | 34.21 |
| Support Level | $15.65 | $1.52 |
| Resistance Level | $16.12 | $1.63 |
| Average True Range (ATR) | 0.58 | 0.08 |
| MACD | 0.32 | -0.00 |
| Stochastic Oscillator | 92.16 | 7.14 |
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.